文献速递贫血与红细胞疾病造血干细胞移植与细胞治疗

阿仑单抗治疗复发免疫性重型再生障碍性贫血:一项II期研究的长期结果

Alemtuzumab in relapsed immune severe aplastic anemia: Long-term results of a phase II study.
PubMed 文献 · Am J Hematol · 2023-04-06

这项II期研究纳入42例既往接受抗胸腺细胞球蛋白(ATG)为基础免疫抑制治疗(IST)后复发的重型再生障碍性贫血(SAA)患者,评估阿仑单抗静脉(28例)或皮下(14例)给药。6个月时18例(43%)获得血液学缓解,静脉组15例(54%)对比皮下组3例(21%)。中位随访6年总生存率67%,部分缓解持久,但医源性免疫抑制可持续长达2年。

要点

  • 复发SAA患者接受阿仑单抗后6个月43%(18/42)获得血液学缓解。
  • 静脉给药缓解率54%(15/28)高于皮下给药21%(3/14)。
  • 6例(14%)在末次随访时无需后续AA治疗或HSCT而维持持久缓解。

核心结论

  • 阿仑单抗可在复发SAA中诱导缓解,部分缓解为长期持久。
  • 但免疫抑制可持续数年,需要长期监测。

研究设计与样本

  • II期临床试验,纳入42例既往完成ATG为基础IST后复发的SAA患者。
  • 阿仑单抗静脉给药28例,皮下给药14例。
  • 主要终点为6个月时血液学缓解,次要终点包括复发、克隆演变和生存。
  • 试验注册于clinicaltrials.gov(NCT00195624),患者入组历时9年,中位随访6年。

主要发现

  • 患者中位年龄32岁,57%为女性。
  • 6个月时18例(43%)获得缓解;静脉组15例(54%)对比皮下组3例(21%)。
  • 6例(14%)在末次随访时无需后续AA定向治疗或HSCT而维持持久长期缓解。
  • 9例出现克隆演变,其中6例为高危克隆演变。
  • 中位随访6年总生存率为67%。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Immune severe aplastic anemia (SAA) is characterized by pancytopenia and immune-mediated bone marrow destruction. SAA may be treated with hematopoietic stem cell transplantation (HSCT) or immunosuppressive therapy (IST). However, 30% of patients treated with IST relapse. We previously reported a clinical trial of alemtuzumab in which more than half of 25 relapsed SAA patients (56%) responded hematologically. Here, we present long-term results of a total of 42 patients. Participants with SAA who had previously completed antithymocyte globulin (ATG)-based IST, but had relapsed, were enrolled on this study. Alemtuzumab was administered intravenously (IV) (n = 28) or subcutaneously (SC) (n = 14). The primary endpoint was hematologic response at 6 months. Secondary endpoints included relapse, clonal evolution, and survival. This trial was registered at clinicaltrials.gov (NCT00195624). Patients were enrolled over 9 years, with median follow-up of 6 years. Median age was 32 years, with 57% being female. At 6 months, 18 patients (43%) achieved response; 15 (54%) of those who received IV compared with 3 (21%) who received SC therapy. Six patients (14%) had durable long-term response without need for subsequent AA-directed therapy or HSCT at last follow-up. Nine patients had clonal evolution, with high-risk evolution occurring in 6. Overall survival was 67% at median follow-up of 6 years. Prolonged iatrogenic immunosuppression was observed as long as 2 years after alemtuzumab administration. Alemtuzumab induces responses in relapsed SAA, some of which are durable long-term. However, immunosuppression can persist for years, requiring long-term monitoring.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Aggarwal N, Manley AL, Shalhoub R, et al. Alemtuzumab in relapsed immune severe aplastic anemia: Long-term results of a phase II study. Am J Hematol. 2023. PMID: 37021397. doi:10.1002/ajh.26924

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。